Inotrem announces €39 Million Series B Financing to Develop First- In-Class Immunology Therapeutics
September 12, 2019
Paris, September 12th. 2019. Inotrem S.A., a biotechnology company specialized in the development of immunotherapies targeting the TREM-1 pathway with potential applications for acute and